According to a story from Benzinga, the pharmaceutical company Inceptua Group has recently announced that the medicine paclitaxel micellar (marketed as Apealea) is now available in Germany. This medication is designated for the treatment of adult patients living with primary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer that is platinum sensitive and has relapsed once. The therapy is to be used in combination with carboplatin.
About Ovarian Cancer
Ovarian cancer can appear on or within the ovary. Ovarian cancer rarely causes distinctive symptoms in its early stages, so many patients are often not diagnosed until an advanced stage in their disease. The risk of getting ovarian cancer is connected to how long a woman has ovulated during her life; women who ovulate for longer periods are at greater risk. Late menopause or early puberty are risk factors, as are not having children, fertility medication, certain genetic variants and mutations (such as BRCA mutations), and exposure to talc, herbicides, and pesticides. Some symptoms of ovarian cancer include fatigue, bloating, a feeling of fullness, loss of appetite, indigestion, abdominal swelling, and pelvic pain. Treatment can include chemo, radiation, surgery, hormone therapy, and immunotherapy. There are many different kinds of ovarian cancer. Five year survival rate is 45 percent in the US. To learn more about ovarian cancer, click here.
About Apealea
Apealea is a Cremophor-free formulation of paclitaxel. The medication is in the midst of being released throughout much of Europe. The Cremophor-free formulation means that patients can enjoy shorter infusion times and a reduced need for premedication. The formulation first earned approval in the European Union in November 2018. In trials, the performance of Apealea was equal to paclitaxel based on Cremophor in the measures of overall survival and progression free survival.
As Apealea continues to appear throughout larger and larger portions of Europe, people living with ovarian cancer, peritoneal cancer, and fallopian tube cancer will have the opportunity to experience a treatment with reduced side effects and treatment burden.
